Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2025-15

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 338 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of Trastuzumab (subcutaneous injection) under a discount contract with German statutory health insurance funds.
  • Conclusion of a framework-type agreement without volume commitment; no exclusivity for any contractor.
Afficher le résumé complet

Open-House procedure by German health insurance funds (led by Techniker Krankenkasse) for discount contracts on Trastuzumab (subcutaneous injection). The procedure is open to all eligible pharmaceutical entrepreneurs throughout the contract term (max. 24 months, 01.08.2025 – 31.07.2027). No estimated contract value is provided; the procedure is not a public procurement subject to EU procurement law but a voluntary publication. Participation is possible at any time during the contract term, with specific deadlines for inclusion in the monthly pharmacy software update.

Risques

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG for the specific drug.
  • Must have a valid marketing authorization for Trastuzumab (subcutaneous injection) in Germany.

Eligibility

  • Must provide a self-declaration confirming eligibility and reliability.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-15

Single lot covering discount contracts for Trastuzumab (subcutaneous injection). All eligible pharmaceutical entrepreneurs can conclude a contract under uniform conditions; no exclusivity is granted. The contract ends at the latest on 31.07.2027, or earlier upon patent expiry/market exclusivity loss.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Date limite

Deadline Jul 30, 2027

Détails de la procédure

Date de publication
19 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
323734-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3